Pharmaron Beijing revenue and financials
¥44.97Change from previous close: +4.63%Absolute change: +¥1.99
In the fiscal year ended December 2025, Pharmaron Beijing reported revenue of ¥14.1B (+14.82% year over year). Net income was ¥1.66B, a net margin of 11.8%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +14.82%
- 2025 vs 2024
- Net income growth
- −7.22%
- 2025 vs 2024
- Net margin
- 11.8%
- 2024: 14.6%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 3,221 | 2,577 | 2,754 | 2,143 | — |
| Depreciation and amortization | 1,181 | 1,049 | 927 | 696 | — |
| Capital expenditure | -2,669 | -2,041 | -2,865 | -2,950 | — |
| Investing cash flow | -4,374 | -2,024 | -2,251 | -2,209 | — |
| Financing cash flow | 377 | -4,797 | 3,915 | -1,417 | — |
| Dividends paid | -531 | -542 | -445 | -405 | — |
| Debt issued | 2,866 | 1,322 | 4,171 | 590 | — |
| Debt repaid | -1,771 | -5,093 | -559 | -613 | — |
| Effect of exchange rates | -3.9 | 78.1 | 11.4 | 73.0 | — |
| Net change in cash | -776 | -4,244 | 4,418 | -1,483 | — |
| Free cash flow | 552 | 536 | -112 | -807 | — |